Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.50 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 10/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 6/20 | 0.41 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.39 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18313115 | 0.93 | CDK2 (0.58) | CDK2CSNK2A1CCNT1CCNKCCNE1 | |
| SCHEMBL20549662 | 0.93 | CDK2 (0.58) | CDK2CSNK2A1CCNT1CCNKCCNE1 | |
| SCHEMBL21472931 | 0.89 | CSNK2A1 (0.63) | CDK2CSNK2A1CCNT1CCNKCCNE1 | |
| SCHEMBL20549702 | 0.87 | CDK2 (0.53) | CDK2CSNK2A1CCNT1CCNKCCNE1 | |
| SCHEMBL18313497 | 0.87 | CDK2 (0.53) | CDK2CSNK2A1CCNT1CCNKCCNE1 | |
| SCHEMBL23609246 | 0.87 | CDK2 (0.47) | CDK2CSNK2A1CCNT1CCNKCCNE1 | |
| SCHEMBL20286069 | 0.87 | CDK2 (0.53) | CDK2CSNK2A1CDK7CDK9CCNH | |
| SCHEMBL20549734 | 0.86 | CDK2 (0.48) | CDK2CSNK2A1CSNK2A2CSNK2BGSK3B | |
| SCHEMBL20549736 | 0.86 | CDK2 (0.48) | CDK2CSNK2A1CSNK2A2CSNK2BGSK3B | |
| SCHEMBL20286071 | 0.85 | CSNK2A1 (0.61) | CDK2CSNK2A1CCNT1CCNKCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | CDK2 63/4885CSNK2A1 145/4885CCNT1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.